Cenyxbiotech
2 known investors
Seoul-based nano-medicine company developing cerium oxide nanozyme therapeutics for brain injury, stroke and inflammation.
Also known as Cenyx Biotech Inc. · Cenyx Biotech, Inc.
Investors · 2
Company profile
researched Aug 2026Cenyx Biotech Inc. is a nano-medicine company headquartered in Seoul, South Korea, established in 2016. It develops nano-biotech agents, classified under biotechnology with sub-industry activity in biopharmaceuticals and pharmaceutical research and development. Its work centers on nanozyme-based drug candidates, including enzyme-type and small-molecule programs, addressing nervous system diseases, cardiovascular diseases and other indications.
The pipeline includes CX-213, listed at IND approval stage with active indications in inflammation and subarachnoid hemorrhage, and CX-301, a preclinical candidate for ischemic stroke, alongside several preclinical nanozyme-e and nanozyme-p programs. A peer-reviewed article in Nanomedicine: Nanotechnology, Biology and Medicine (September 2022) described CX201, ultrasmall cerium oxide nanoparticles coated with 6-aminocaproic acid and polyvinylpyrrolidone, reporting multi-enzymatic antioxidant function, neuroprotective effects in vitro, and improved functional recovery in a traumatic brain injury animal model after a single intravenous dose.
The company is at Series B stage and is backed by institutional venture investors. Reported capital raised in April 2026 is designated for accelerating global clinical trials of the CX213 pipeline and establishing drug product manufacturing facilities.
Traction
Reported revenue of $10.6 million for the fiscal year ended December 31, 2020, with operating and net losses reported for fiscal years 2019 and 2020. The pipeline includes one candidate at IND approval stage (CX-213) and multiple preclinical programs. Investor backing includes SBI Investment, Partners Investment, AJU IB Investment, CKD Venture Capital, SL Investment, InterValue Partners, WONIK Investment Partners and Scale Up Partners.
Latest developments
In April 2026 the company raised KRW 12.5 billion in venture funding led by new investor Scale Up Partners, with returning investors participating. The proceeds are earmarked for accelerating global clinical trials of the CX213 pipeline and building drug product production facilities.
▸Full profile — market position, technology, go-to-market, geography
Market position
Cenyx Biotech is a Series B-stage private biotechnology company in Seoul with a headcount in the 10-50 range, positioned in nano-medicine for nervous system and cardiovascular indications. Its lead asset has reached IND approval, with the remainder of the disclosed pipeline at preclinical stage.
Technology
Cenyx Biotech's platform is built on nanozyme chemistry — ultrasmall inorganic nanoparticles with enzyme-like catalytic activity. Its published CX201 candidate consists of core cerium oxide nanoparticles coated with 6-aminocaproic acid and polyvinylpyrrolidone synthesized in the aqueous phase, with a core diameter of approximately 3.49 nm and a hydrodynamic diameter of approximately 6.49 nm, exhibiting multi-enzymatic antioxidant function, physiological stability and cell viability. The rationale targets free radicals as a mediator of secondary injury after traumatic brain injury, an area where conventional antioxidants have shown modest clinical efficacy. Pipeline drug types are classified as enzyme and small molecule.
Go-to-market
The candidate therapies address patients with acute neurological and vascular conditions, including traumatic brain injury, subarachnoid hemorrhage, ischemic stroke and inflammation, indications for which the published literature notes an absence of approved therapies for secondary injury after traumatic brain injury.
Geography
Headquartered in Seoul, South Korea. Funding raised in April 2026 is intended in part to support global clinical trials.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsPipeline listing records CX-213, with active indications in inflammation and subarachnoid hemorrhage, at IND approval as its highest phase.
Cenyx Biotech raised KRW 12.5 billion in venture funding from new investor Scale Up Partners, with returning investors SBI Investment, Partners Investment, AJU IB Investment, CKD Venture Capital, SL Investment, InterValue Partners and other unspecified investors participating. Proceeds are to accelerate global clinical trials for the CX213 pipeline and establish drug product production facilities.
An article in Nanomedicine: Nanotechnology, Biology and Medicine reported that CX201, ultrasmall polymer-coated cerium oxide nanoparticles, showed multi-enzymatic antioxidant function, in vitro neuroprotection, and significantly improved functional recovery after a single intravenous injection in a traumatic brain injury animal model, with reduced lipid peroxidation and inflammatory cell recruitment.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- Cenyx Biotech Inc. Asset Profile | Preqinpreqin.com · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cenyxbiotech do?
- Seoul-based nano-medicine company developing cerium oxide nanozyme therapeutics for brain injury, stroke and inflammation.
- Who are Cenyxbiotech's investors?
- Cenyxbiotech's investors include Aju IB Invesment Corporation, Kiwoom Investment.